A "bulldozer" driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy

被引:12
|
作者
Zhang, Huijuan [1 ,2 ,3 ,5 ]
Wang, Yaping [1 ]
Zhu, Ling [1 ,2 ]
Qi, Zijun [1 ]
Cao, Kexuan [1 ]
Chang, Junbiao [3 ,4 ,5 ]
Hou, Lin [1 ,2 ,5 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou, Peoples R China
[2] Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou, Henan Province, Peoples R China
[3] Collaborat Innovat Ctr New Drug Res & Safety Evalu, Zhengzhou, Henan Province, Peoples R China
[4] Zhengzhou Univ, Sch Chem & Mol Engn, Zhengzhou, Peoples R China
[5] Zhengzhou Univ, Sch Pharmaceut Sci, 100, Kexue Rd, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
PDAC; Tumor matrix barrier; ICD; Autophagy inhibition; Immunotherapy; IMMUNOGENIC CELL-DEATH;
D O I
10.1016/j.jconrel.2023.07.014
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Immune evasion is a major obstacle for pancreatic ductal adenocarcinoma (PDAC) therapy. Inhibition of autophagy can improve antigen presentation and enlarge immunogenic cell death (ICD) effect to generate a strong anti-tumor immune response. However, abundant extracellular matrix dominated by hyaluronic acid (HA) hinders the deep penetration of autophagy inhibitors and ICD inducers. Herein, an intelligent autophagy inhibitor hydroxychloroquine (HCQ) and chemotherapeutic drug doxorubicin (DOX) co-loaded "bulldozer" (HD@HH/EcN) driven by anoxic bacteria was constructed for PDAC chemo-immunotherapy. Results demonstrated that probiotic Escherichia coli 1917 (EcN) could carry hyaluronidases (HAases)-hybrided albumin nanoparticles (HD@HH) to reach PDAC tumor tissue quickly and accurately. Thereafter, HAases can efficiently cleave the tumor matrix barrier and promote HD@HH/EcN to accumulate at tumor hypoxic core significantly. After that, high level of glutathione (GSH) in tumor microenvironment (TME) induces intermolecular disulfide bond in HD@HH nanoparticles breakage, to precisely release HCQ and DOX. DOX can induce ICD effect. Meanwhile, HCQ can amplify DOX induced ICD effect by inhibiting tumor autophagy, which further increase cell surface expression of major histocompatibility complex class I (MHC-I) and augment recruitment of CD8+ T cell to improve immunosuppressive TME. This study provides a new strategy for PDAC chemo-immunotherapy.
引用
收藏
页码:660 / 671
页数:12
相关论文
共 50 条
  • [1] Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer
    Gomez, GG
    Hutchison, RB
    Kruse, CA
    CANCER TREATMENT REVIEWS, 2001, 27 (06) : 375 - 402
  • [2] Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
    Melief, Cornelis J. M.
    CELL REPORTS MEDICINE, 2022, 3 (10)
  • [3] CHEMO-IMMUNOTHERAPY
    BUCHANAN, JG
    CASEY, TP
    NEW ZEALAND MEDICAL JOURNAL, 1974, 79 (511) : 803 - 804
  • [4] ADJUVANT CHEMO-IMMUNOTHERAPY IN BREAST-CANCER
    JORGENSEN, OG
    GUNDERSEN, S
    ACTA CHIRURGICA SCANDINAVICA, 1981, : 109 - 109
  • [5] Chemo-immunotherapy in advanced head and neck cancer
    Recchia, F
    Sica, G
    De Filippis, S
    Rosselli, M
    Pompili, P
    Saggio, G
    Rea, S
    ANTICANCER RESEARCH, 1999, 19 (1B) : 773 - 777
  • [6] Chemo-Immunotherapy: A New Trend in Cancer Treatment
    Sordo-Bahamonde, Christian
    Lorenzo-Herrero, Seila
    Gonzalez-Rodriguez, Ana P.
    Martinez-Perez, Alejandra
    Rodrigo, Juan P.
    Garcia-Pedrero, Juana M.
    Gonzalez, Segundo
    CANCERS, 2023, 15 (11)
  • [7] COMBINED CHEMO-IMMUNOTHERAPY IN CANCER AND HEMATOSARCOMA OF THE STOMACH
    BRITSIS, FA
    ZAKENFELD, GK
    KRAMPE, RA
    BERZINYA, VY
    PURKALNE, TS
    VOPROSY ONKOLOGII, 1980, 26 (05) : 72 - 77
  • [8] CHEMO-IMMUNOTHERAPY OF MURINE BLADDER-CANCER
    STOGDILL, BJ
    LAMM, DL
    LIVINGSTON, RB
    INVESTIGATIVE UROLOGY, 1981, 19 (03): : 179 - 181
  • [9] Mathematical model creation for cancer chemo-immunotherapy
    de Pillis, Lisette
    Fister, K. Renee
    Gu, Weiqing
    Collins, Craig
    Daub, Michael
    Gross, David
    Moore, James
    Preskill, Benjamin
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2009, 10 (03) : 165 - 184
  • [10] ADJUVANT CHEMO-IMMUNOTHERAPY
    BOWMAN, DM
    CANADIAN JOURNAL OF SURGERY, 1981, 24 (04) : 375 - 378